What is NDC 67184-0572?

67184-0572 is the product NDC for Mirabgeorn (mirabegron), Mirabegron 50 mg/1 tablet, film coated, extended release, listed with the FDA by Qilu Pharmaceutical Co., Ltd.. It has 2 package NDCs, shown above in 10- and 11-digit form.

Qilu Pharmaceutical Co., Ltd., NDC labeler code 67184. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Mirabgeorn?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Mirabgeorn NDC 67184-0572 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)67184-0572Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67184-0572Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
67184-0572-1	6718405720167184057201	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (67184-0572-1)Marketed from Jun 30, 2025
67184-0572-2	6718405720267184057202	90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (67184-0572-2)Marketed from Jun 30, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mirabgeorn
Generic name (nonproprietary): mirabegron
Active ingredients: Mirabegron — 50 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Qilu Pharmaceutical Co., Ltd.NDC labeler code 67184
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217989
Marketing start: Jun 30, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic beta3-Agonists (Mechanism)Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
Identifiers: Product ID 67184-0572_b4283ace-4312-4cab-97c2-0722339d75b9SPL ID b4283ace-4312-4cab-97c2-0722339d75b9SPL set ID 98247602-29b9-4621-8eeb-519e40b883b9RxCUI 1300791, 1300801UNII MVR3JL3B2VUPC 0367184057214, 0367184057221, 0367184057122, 0367184057115
Pharmacologic class: beta3-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N467184057201 followed by a unit qualifier and the quantity

Package 67184-0572-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 21, 2025.

Indications (excerpt from the label)

Mirabegron extended-release tablets are beta-3 adrenergic agonists indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Extended-Release Tablets Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indic…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 67184-0572

What is NDC 67184-0572?: 67184-0572 is the product NDC for Mirabgeorn (mirabegron), Mirabegron 50 mg/1 tablet, film coated, extended release, listed with the FDA by Qilu Pharmaceutical Co., Ltd.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Mirabgeorn (Mirabegron).
What is the active ingredient?: Mirabegron.
Who is the labeler?: Qilu Pharmaceutical Co., Ltd., NDC labeler code 67184. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Mirabgeorn?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under ANDA 217989

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217989
Product	Strength	Form · route	Labeler	Product NDC
Mirabegron	Mirabegron 25 mg/1	Tablet, Film coated, Extended releaseOral	Qilu Pharmaceutical Co., Ltd.	67184-0571

Mirabgeorn (Mirabegron) NDC 67184-0572